This Article Full Text (PDF) Correction Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Middleton, P. Articles by Alton, E. Search for Related Content PubMed PubMed Citation Articles by Middleton, P. Articles by Alton, E.

Original Articles

Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth

Liposome-mediated gene transfer is commonly used for in vitro transfection of deoxyribonucleic acid (DNA) into mammalian cells. We and others have recently demonstrated that this can be an effective method for in vivo delivery of plasmid DNA containing the human cystic fibrosis transmembrane conductance regulator (CFTR) gene to mouse models of cystic fibrosis (CF). This suggests that cationic liposomes may be useful for transferring CFTR complementary DNA (cDNA) into the airways of CF subjects. In such trials, measurement of nasal potential difference (PD) will be used to monitor the efficacy of correction of the CF bioelectric defect and to provide a sensitive assay of epithelial integrity [corrected]. We therefore assessed whether the cationic liposome DC-Chol: DOPE altered nasal ion transport parameters, in six normal and three CF subjects. Lung function was also measured as a further marker of safety. Finally, as CF airways are chronically infected, we studied whether DC-Chol:DOPE or DC-Chol:DOPE-DNA complexes altered the bacterial growth and sensitivities of CF sputum. No significant effect was seen on any of these parameters, suggesting that DC-Chol:DOPE may be appropriate for use in human trials of liposome-mediated gene therapy for CF.

This article has been cited by other articles:

				P. G. Middleton, K. A. Pollard, E. Donohoo, J. R. Wheatley, D. M. Geddes, and E. W. Alton Airway Surface Liquid Calcium Modulates Chloride Permeability in the Cystic Fibrosis Airway Am. J. Respir. Crit. Care Med., November 15, 2003; 168(10): 1223 - 1226. [Abstract] [Full Text] [PDF]

				J. P. CLANCY, Z. BEBOK, F. RUIZ, C. KING, J. JONES, L. WALKER, H. GREER, J. HONG, L. WING, M. MACALUSO, et al. Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1683 - 1692. [Abstract] [Full Text] [PDF]

				P.G. Middleton, K.A. Pollard, and J.R. Wheatley Hypertonic saline alters ion transport across the human airway epithelium Eur. Respir. J., February 1, 2001; 17(2): 195 - 199. [Abstract] [Full Text] [PDF]

				P. G Middleton and E. W F W Alton Gene therapy for cystic fibrosis: which postman, which box? Thorax, March 1, 1998; 53(3): 197 - 199. [Abstract] [Full Text]

				G. Melillo, M. Scoccianti, I. Kovesdi, J. Safi Jr, T. Riccioni, and M. C Capogrossi Gene therapy for collateral vessel development Cardiovasc Res, September 1, 1997; 35(3): 480 - 489. [Abstract] [Full Text] [PDF]